🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. ADX-629 (Open-label)

    Aldeyra Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  2. AEF0117

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Abuse

    phase 2 small molecule completed

    1 trial

  3. AG-120/S95031 250mg film-coated tablet, IMFINZI 50 mg/mL concentrate for solution for infusion., Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    The George Institute

    Locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation

    phase 2 small molecule active

    1 trial

  4. AGMB-129

    Agomab Therapeutics NV

    Fibrostenotic Crohn's Disease

    phase 2 small molecule active

    2 trials

  5. AK104

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  6. AK104, nab-paclitaxel, carboplatin

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  7. AK112, Cadonilimab, nab-paclitaxel, gemcitabine

    Akeso

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  8. ALDESLEUKIN , Tumor Intiltrating Lymphocytes (TIL) – VHIO, FLUDARABINE , CYCLOPHOSPHAMIDE

    The George Institute

    Germ Cell Tumors refractory to salvage chemotherapy

    phase 2 small molecule active

    1 trial

  9. ALECTINIB

    Hoffmann-La Roche

    ALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment available

    phase 2 small molecule active

    1 trial

  10. ALG-000184, ALG-000184 Placebo, Tenofovir Disoproxil Placebo, Tenofovirdisoproxil Amarox 245 mg Filmtabletten

    Aligos Therapeutics

    Chronic Hepatitis B Virus Infection

    phase 2 small molecule active

    1 trial

  11. ALN-4324

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule active

    1 trial

  12. ALN-ANG3

    Regeneron UK Limited

    Diabetic Kidney Disease (DKD)

    phase 2 small molecule active

    1 trial

  13. ALN-CIDEB

    Regeneron UK Limited

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 2 small molecule active

    1 trial

  14. ALN-HSD

    Regeneron UK Limited

    Metabolic Dysfunction-Associated SteatoHepatitis (MASH)

    phase 2 small molecule active

    1 trial

  15. ALN-KHK

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule terminated

    1 trial

  16. ALN-PNP

    Regeneron UK Limited

    Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    phase 2 small molecule active

    1 trial

  17. ALXN 2050, ALXN2050 Placebo Tablets

    Alexion Europe SAS

    Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)

    phase 2 small molecule active

    1 trial

  18. AMINOHIPPURIC ACID, OMNIPAQUE 300 mg I/ml soluzione iniettabile, Felzartamab

    Istituto Gentili S.r.l.

    Membranous nephropathy

    phase 2 small molecule active

    1 trial

  19. AMO959, ENZALUTAMIDE, Enzalutamide, Prednison 5 mg GALEN® Tabletten, -, DEGARELIX, RELUGOLIX, Prednison acis 5 mg, Pluvicto 1 000 MBq/mL solution for injection/infusion, ABIRATERONE, Abiraterone, PIFLUFOLASTAT (18F), AMO959, GOZETOTIDE, DEGARELIX

    Novartis Pharmaceuticals

    PSMA-positive mCRPC with prior exposure to at least one prior ARPI

    phase 2 small molecule active

    1 trial

  20. AN OPEN-LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE SAFETY AND EFFICACY IN PARTICIPANTS TREATED WITH CRN04894

    Lacuna Pharma Pty Ltd

    CONGENITAL ADRENAL HYPERPLASIA

    phase 2 other active

    1 trial

  21. AN OPEN-LABEL, MULTICENTER STUDY IN MALE PEDIATRIC PATIENTS WITH CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY (CALD) TO ASSESS THE EFFECTS OF MIN-102 TREATMENT ON DISEASE PROGRESSION PRIOR TO HUMAN STEM CELL TRANSPLANT (HSCT)

    Minoryx Therapeutics S.L.

    CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY (CALD)

    phase 2 other active

    1 trial

  22. ANEB-001

    Anebulo Pharmaceuticals

    Acute Cannabinoid Intoxication

    phase 2 small molecule completed

    1 trial

  23. AP1189 Tablet, AP1189 Tablet, AP1189 Tablet, Matching Placebo (tablets), Methotrexat-Ebewe, 2,5 mg, tabletki

    Lacuna Pharma Pty Ltd

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  24. AP31969, AP31969, The placebo tablets contain the same excipient as in the active IMP, but without AP31969. All tablet strengths containing AP31969 as well as placebo tablets are visually identical., AP31969, AP31969

    Lacuna Pharma Pty Ltd

    Atrial fibrillation

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources